Merck & Co., Inc. $MRK Stock Sold by Cullen Capital Management LLC

Merck & Co., Inc. logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Cullen Capital Management cut its Merck stake by 8.8% in the third quarter, selling 178,420 shares; it still held 1.84 million shares worth about $267 million.
  • Analysts gave Merck a “Moderate Buy” consensus, with an average price target of $155.74; 17 analysts rated the stock Buy or Strong Buy, 11 Hold, and one Sell.
  • Merck’s latest quarter beat expectations, reporting EPS of $2.49 versus $2.09 expected and revenue of $18.09 billion, up 4.7% year over year.
  • MarketBeat previews the top five stocks to own by December 1st.

Cullen Capital Management LLC lessened its stake in shares of Merck & Co., Inc. (NYSE:MRK - Free Report) by 8.8% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,838,375 shares of the company's stock after selling 178,420 shares during the quarter. Merck & Co., Inc. accounts for about 2.7% of Cullen Capital Management LLC's holdings, making the stock its 4th biggest holding. Cullen Capital Management LLC owned approximately 0.07% of Merck & Co., Inc. worth $267,134,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds also recently bought and sold shares of the stock. Round Rock Advisors LLC raised its stake in shares of Merck & Co., Inc. by 0.7% in the 2nd quarter. Round Rock Advisors LLC now owns 9,901 shares of the company's stock valued at $1,272,000 after acquiring an additional 66 shares during the period. Cypress Wealth Services LLC lifted its holdings in shares of Merck & Co., Inc. by 0.5% in the 3rd quarter. Cypress Wealth Services LLC now owns 13,807 shares of the company's stock worth $1,960,000 after acquiring an additional 69 shares during the last quarter. Code Waechter LLC lifted its holdings in shares of Merck & Co., Inc. by 3.4% in the 3rd quarter. Code Waechter LLC now owns 2,179 shares of the company's stock worth $317,000 after acquiring an additional 71 shares during the last quarter. Quest 10 Wealth Builders Inc. lifted its holdings in shares of Merck & Co., Inc. by 12.2% in the 3rd quarter. Quest 10 Wealth Builders Inc. now owns 699 shares of the company's stock worth $102,000 after acquiring an additional 76 shares during the last quarter. Finally, Cascade Financial Partners LLC boosted its position in shares of Merck & Co., Inc. by 0.5% during the 2nd quarter. Cascade Financial Partners LLC now owns 14,746 shares of the company's stock worth $1,895,000 after purchasing an additional 80 shares during the period. Hedge funds and other institutional investors own 76.07% of the company's stock.

Analyst Ratings Changes

Several analysts recently weighed in on MRK shares. Freedom Broker lifted their target price on shares of Merck & Co., Inc. from $125.00 to $140.00 and gave the company a "hold" rating in a report on Monday, November 2nd. Berenberg Bank boosted their target price on Merck & Co., Inc. from $127.00 to $137.00 and gave the company a "hold" rating in a research report on Friday, September 11th. Jefferies Financial Group upped their price target on Merck & Co., Inc. from $152.00 to $175.00 and gave the stock a "buy" rating in a research note on Thursday, August 20th. Leerink Partners upped their price target on Merck & Co., Inc. from $127.00 to $161.00 and gave the stock an "outperform" rating in a research note on Wednesday, September 9th. Finally, HSBC raised their price target on Merck & Co., Inc. from $150.00 to $172.00 and gave the stock a "buy" rating in a research report on Thursday, September 10th. One analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating, eleven have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Merck & Co., Inc. has an average rating of "Moderate Buy" and a consensus price target of $155.74.

Check Out Our Latest Stock Report on Merck & Co., Inc.

Insider Buying and Selling at Merck & Co., Inc.

In related news, EVP Richard Deluca sold 58,185 shares of Merck & Co., Inc. stock in a transaction that occurred on Thursday, November 12th. The shares were sold at an average price of $148.01, for a total value of $8,611,961.85. Following the completion of the transaction, the executive vice president owned 112,955 shares in the company, valued at approximately $16,718,469.55. The trade was a 34.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 0.17% of the company's stock.

Merck & Co., Inc. Stock Performance

NYSE MRK opened at $144.49 on Tuesday. The company has a debt-to-equity ratio of 1.11, a current ratio of 1.35 and a quick ratio of 1.14. The company has a market cap of $356.20 billion, a P/E ratio of 148.96, a P/E/G ratio of 6.74 and a beta of 0.13. The stock has a 50-day moving average of $146.04 and a two-hundred day moving average of $128.80. Merck & Co., Inc. has a 1-year low of $92.11 and a 1-year high of $156.92.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last issued its quarterly earnings results on Thursday, October 29th. The company reported $2.49 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.09 by $0.40. The business had revenue of $18.09 billion for the quarter, compared to analysts' expectations of $17.33 billion. Merck & Co., Inc. had a net margin of 3.64% and a return on equity of 16.73%. The business's quarterly revenue was up 4.7% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.58 earnings per share. As a group, analysts anticipate that Merck & Co., Inc. will post 2.82 EPS for the current year.

Merck & Co., Inc. Company Profile

(Free Report)

Merck & Co., Inc. is a global pharmaceutical company that develops and markets prescription medicines, vaccines, biologic therapies and animal-health products. The company's research and commercial activities span areas including oncology, infectious diseases, vaccines, cardiovascular disease and immunology. Its products include the cancer medicine Keytruda and the Gardasil vaccine. Founded in the United States in 1891, Merck & Co. became an independent company in 1917. It is headquartered in Rahway, New Jersey, and operates internationally.

Read More

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK - Free Report).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Merck & Co., Inc. Right Now?

Before you consider Merck & Co., Inc., you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Merck & Co., Inc. wasn't on the list.

While Merck & Co., Inc. currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Best Space Stocks to Own in 2026 Cover

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines